Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203351 | 0.92 | AKR1C3 (0.52) | AKR1C3AKR1C2ATMPTGS2ENPP2 | |
| SCHEMBL758323 | 0.91 | ATM (0.66) | AKR1C3AKR1C2ATMPTGS2L3MBTL1 | |
| SCHEMBL15624757 | 0.89 | ATM (0.59) | AKR1C3AKR1C2ATMPTGS2L3MBTL1 | |
| SCHEMBL12267631 | 0.89 | CYP2A6 (0.56) | AKR1C3AKR1C2ATMPTGS2SMN1; SMN2 | |
| SCHEMBL3883747 | 0.87 | AKR1C3 (0.49) | AKR1C3AKR1C2ATMPTGS2ENPP2 | |
| SCHEMBL16289366 | 0.87 | AKR1C3 (0.49) | AKR1C3AKR1C2ATMPTGS2ENPP2 | |
| SCHEMBL10484185 | 0.87 | AKR1C3 (0.49) | AKR1C3AKR1C2ATMPTGS2G6PD | |
| SCHEMBL8035317 | 0.87 | ENPP2 (0.61) | AKR1C3AKR1C2ATMPTGS2ENPP2 | |
| SCHEMBL12278103 | 0.85 | AKR1C3 (0.47) | AKR1C3AKR1C2ATMPTGS2ENPP2 | |
| SCHEMBL12260002 | 0.85 | AKR1C3 (0.47) | AKR1C3AKR1C2ATMPTGS2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | AKR1C3 1874/4885AKR1C2 2306/4885ATM 2778/4885 |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC7 | AKR1C3 2638/4885AKR1C2 2894/4885ATM 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.